CVS Health Corporation
95.38USD
-0.6900 (-0.72%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $1.62▼ | $1.71 | 2 | 17 |
| Next quarter | $1.29▼ | $1.33 | 6 | 12 |
| Current year | $7.97▲ | $7.43 | 22 | 0 |
| Next year | $8.51▲ | $8.37 | 17 | 3 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $1.85 | $2.58 | +0.73 (+39.4%) |
| 2026-03-31 | $2.21 | $2.57 | +0.36 (+16.5%) |
| 2025-12-31 | $1 | $1.09 | +0.09 (+9.4%) |
| 2025-09-30 | $1.36 | $1.6 | +0.24 (+17.9%) |
363 ratings from 42 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Buy | $126 $118 | Sep 3, 2026 |
| Argus Research | Maintained | Buy | $104 $114 | Aug 19, 2026 |
| JP Morgan | Maintained | Overweight | $111 $118 | Aug 12, 2026 |
| UBS | Maintained | Buy | $122 $126 | Aug 6, 2026 |
| Evercore ISI Group | Maintained | Outperform | $130 $125 | Aug 6, 2026 |
| Barclays | Maintained | Overweight | $106 $108 | Aug 6, 2026 |
| UBS | Maintained | Buy | $115 $122 | Jul 25, 2026 |
| Truist Securities | Maintained | Buy | $108 $118 | Jul 14, 2026 |
| Wells Fargo | Maintained | Overweight | $103 $123 | Jul 13, 2026 |
| RBC Capital | Maintained | Outperform | $107 $113 | Jul 9, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $100 $110 | Jul 7, 2026 |
| B of A Securities | Maintained | Buy | $100 $110 | Jun 23, 2026 |
| Mizuho | Maintained | Outperform | $110 $115 | Jun 8, 2026 |
| Morgan Stanley | Maintained | Overweight | $106 $111 | Jun 4, 2026 |
| Truist Securities | Maintained | Buy | $102 $108 | Jun 1, 2026 |
| Barclays | Maintained | Overweight | $101 $106 | May 26, 2026 |
| Mizuho | Maintained | Outperform | $102 $110 | May 20, 2026 |
| Morgan Stanley | Maintained | Overweight | $93 $106 | May 14, 2026 |
| Bernstein | Maintained | Outperform | $94 $106 | May 13, 2026 |
| JP Morgan | Maintained | Overweight | $101 $111 | May 12, 2026 |
| TD Cowen | Maintained | Buy | $105 $110 | May 11, 2026 |
| Wells Fargo | Maintained | Overweight | $102 $103 | May 8, 2026 |
| UBS | Maintained | Buy | $97 $100 | May 7, 2026 |
| RBC Capital | Maintained | Outperform | $93 $107 | May 7, 2026 |
| Barclays | Maintained | Overweight | $93 $101 | May 7, 2026 |
67 filings from 24 insiders · 16 buy / 2 sell over 6m
Officers and directors of CVS, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| ROBBINS LARRYDirector | Sellindirect | 3.37M | $93.45 | $317.47M | May 21, 2026 |
| BALSER JEFFREY R M.D., PH.D.Director | Grant | 2.1k | $97.15 | $200k | May 14, 2026 |
| SANSONE GUY PDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| BROWN C DAVID IIDirector | Grant | 1.5k | $97.15 | $150k | May 14, 2026 |
| AGUIRRE FERNANDODirector | Grant | 1.6k | $97.15 | $152k | May 14, 2026 |
| NORWALK LESLIE VDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| KIRBY JOHN SCOTTDirector | Grant | 1.4k | $97.15 | $141k | May 14, 2026 |
| MANDADI TILAKOfficer | Sell | 69.6k | $89.58 | $6.23M | May 8, 2026 |
| COMPTON-PHILLIPS AMYOfficer | Grant | 5.6k | $71.82 | $400k | Mar 31, 2026 |
| MANDADI TILAKOfficer | Grant | 22.3k | $71.82 | $1.60M | Mar 31, 2026 |
| SHAH PREM SOfficer | Grant | 25.1k | $71.82 | $1.80M | Mar 31, 2026 |
| CLARK JAMES DAVIDOfficer | Grant | 11.1k | $71.82 | $800k | Mar 31, 2026 |
| NEWMAN BRIANChief Financial Officer | Grant | 19.5k | $71.82 | $1.40M | Mar 31, 2026 |
| JOYNER JOHN DAVIDChief Executive Officer | Grant | 86.3k | $71.82 | $6.20M | Mar 31, 2026 |
| NELSON STEVEN HOfficer | Grant | 22.3k | $71.82 | $1.60M | Mar 31, 2026 |
| KHICHI SAMRAT SGeneral Counsel | Grant | 12.5k | $71.82 | $900k | Mar 31, 2026 |
| CAPOZZI HEIDI BOfficer | Grant | 10.0k | $71.82 | $720k | Mar 31, 2026 |
| GALLINA JOHN EDirector | Grant | 582 | $71.86 | $42k | Mar 19, 2026 |
| SHULMAN DOUGLAS HDirector | Grant | 1.7k | $76.04 | $126k | Nov 20, 2025 |
| BALSER JEFFREY R M.D., PH.D.Director | Grant | 1.8k | $76.04 | $135k | Nov 20, 2025 |
No analyst notes on CVS yet.
Analyst Ratings
25 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 6 | 18 | 3 | 0 | 0 | Buy1.89 |
| 1 mo ago | 6 | 18 | 3 | 0 | 0 | Buy1.89 |
| 2 mo ago | 6 | 18 | 4 | 0 | 0 | Buy1.93 |
| 3 mo ago | 6 | 18 | 4 | 0 | 0 | Buy1.93 |